Vaccine Development (HIV)

"Enhancement of Mucosal Immune Responses to HIV Gp160."

Published in AIDS Weekly, June 14th, 1999

NIH Grant Number: 1R21AI44290-01. Grant Expires: September 29, 2000. Principle Investigator: R.M. Buller. Performing Organization: St. Louis University, 221 N. Grand Blvd., St. Louis, Missouri 63103. Description: "Epitopes that induce protective immunity against human immunodeficiency virus (HIV) have not yet been identified, nor have the immune effector mechanisms that can prevent or at least control initial infection. In view of these difficulties, an attractive strategy for HIV vaccine development is one that permits expression of multiple HIV proteins and elicits a multifaceted immune response. Easily engineered, deoxyribonucleic acid...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1999-06-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry